Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is...

Полное описание

Библиографические подробности
Главные авторы:	Andersson, U, Smith, D, Jeyakumar, M, Butters, T, Borja, M, Dwek, R, Platt, F
Формат:	Journal article
Язык:	English
Опубликовано:	2004

Схожие документы

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
по: Ulrika Andersson, и др.
Опубликовано: (2004-08-01)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
по: Jeyakumar, M, и др.
Опубликовано: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
по: Andersson, U, и др.
Опубликовано: (2000)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
по: Baek, R, и др.
Опубликовано: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
по: Baek, R, и др.
Опубликовано: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
по: Platt, F, и др.
Опубликовано: (2003)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
по: Jeyakumar, M, и др.
Опубликовано: (2001)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
по: Kasperzyk, J, и др.
Опубликовано: (2004)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
по: Kasperzyk, J, и др.
Опубликовано: (2004)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
по: Baek, R, и др.
Опубликовано: (2005)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
по: Lowe, J, и др.
Опубликовано: (2005)

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
по: Lachmann, R, и др.
Опубликовано: (2006)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
по: Awan, F, и др.
Опубликовано: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
по: Elliot-Smith, E, и др.
Опубликовано: (2008)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
по: Pelled, D, и др.
Опубликовано: (2003)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
по: Kaya, E, и др.
Опубликовано: (2020)

New developments in treating glycosphingolipid storage diseases.
по: Platt, F, и др.
Опубликовано: (2005)

Substrate reduction therapy
по: Platt, F, и др.
Опубликовано: (2007)

Substrate reduction therapy.
по: Platt, F, и др.
Опубликовано: (2008)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
по: Rountree, J, и др.
Опубликовано: (2009)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
по: Denny, C, и др.
Опубликовано: (2010)

Infantile Sandhoff's disease
по: K Sass, и др.
Опубликовано: (2009-08-01)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
по: Jeyakumar, M, и др.
Опубликовано: (2002)

Storage solutions: treating lysosomal disorders of the brain.
по: Jeyakumar, M, и др.
Опубликовано: (2005)

An inducible mouse model of late onset Tay-Sachs disease.
по: Jeyakumar, M, и др.
Опубликовано: (2002)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
по: Richardson, K, и др.
Опубликовано: (2016)

Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model
по: Evan Woodley, и др.
Опубликовано: (2019-03-01)

Dysregulation of the NLRP3 Inflammasome and Promotion of Disease by IL-1β in a Murine Model of Sandhoff Disease
по: Nick Platt, и др.
Опубликовано: (2025-01-01)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
по: te Vruchte, D, и др.
Опубликовано: (2010)

An Inducible Mouse Model of Late Onset Tay–Sachs Disease
по: Mylvaganam Jeyakumar, и др.
Опубликовано: (2002-08-01)

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
по: Andersson, U, и др.
Опубликовано: (2004)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
по: Platt, F, и др.
Опубликовано: (2001)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
по: van der Spoel, A, и др.
Опубликовано: (2002)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
по: Karen M Ashe, и др.
Опубликовано: (2011-01-01)

Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics
по: Emmanuelle Lecommandeur, и др.
Опубликовано: (2020-12-01)

Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation.
по: Mellor, H, и др.
Опубликовано: (2003)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
по: Jeyakumar, M, и др.
Опубликовано: (2003)

Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease.
по: Yasuhiro Ogawa, и др.
Опубликовано: (2013-01-01)

Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage.
по: Yasuhiro Ogawa, и др.
Опубликовано: (2017-01-01)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
по: Priestman, D, и др.
Опубликовано: (2008)